CellaVision AB (publ) in brief
CellaVision AB (publ) is a listed company in the Medical Devices industry, based in Sweden. It was founded in 1994. Its last known market value was $490 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $77 M and a net profit of $16 M, about 20 cents of profit for every dollar of sales. Its shares trade under the symbol CEVI.ST (Stockholm).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CellaVision AB (publ)
CellaVision AB (publ) is a provider of digital solutions company for medical microscopy in the field of haematology. The headquarters is in Sweden.
CellaVision AB (publ) company annual revenue was 639 million SEK, annual net income was 118 million SEK as on Dec-2022.
CellaVision AB (publ) timeline
- 1994
- 🏁· approximateFounded
- 2014
- •Legal Entity Identifier issuedLEI 529900IUBZBZ0HXFJ114 registered.
Events of CellaVision AB (publ) from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Sweden: #118 (Jan 2020) · #141 (Jan 2021) · #171 (Jan 2022) · #162 (Dec 2022) · #156 (Jul 2023) · #166 (Jan 2024)
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- 20.2%
- Operating margin
- 26.6%
- Return on equity
- 16.2%
- Liabilities / assets
- 18.9%
- Revenue growth
- +12.9%
- R&D / revenue
- 12.9%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $77M | +12.9% | $21M | $16M | 20.2% |
| Dec 2024 | $68M | — | $17M | $13M | 19.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $20M | $2M | $19M | $0.65 | — |
| Dec 2024 | $19M | $1M | $18M | $0.56 | — |
Annual results
- Revenue
- $77 M
- Operating income
- $21 M
- Net income
- $16 M
For year ending December-2025 · source: official annual report (ESEF)
Balance sheet
- Total assets
- $119 M
- Total liabilities
- $23 M
- Total equity
- $96 M
As of December-2025
Mutual funds holding CellaVision AB (publ)#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇸🇪 AMF Aktiefond SmåbolagAMF Fonder AB | 804,300 | $11 M | — | 0.86% | +26% | Jun 30, 2026 |
| 🇸🇪 SEB Sverigefond Småbolag Chans/RiskSEB Funds AB | 784,678 | $11 M | — | 0.50% | no change | Jun 30, 2026 |
| 🇸🇪 Case All Star SmåbolagCase Kapitalförvaltning AB | 698,455 | $10 M | — | 2.9% | no change | Jun 30, 2026 |
| 🇸🇪 Swedbank Robur ExportfondSwedbank Robur Fonder AB | 499,396 | $7 M | — | 0.62% | no change | Jun 30, 2026 |
| 🇸🇪 Länsförsäkringar Småbolag Sverige VisionLänsförsäkringar Fondförvaltning AB | 360,587 | $5 M | — | 0.54% | no change | Jun 30, 2026 |
| 🇸🇪 Handelsbanken Norden Index CriteriaHandelsbanken Fonder AB | 307,023 | $4 M | — | 0.11% | no change | Jun 30, 2026 |
| 🇸🇪 Lannebo Hälsa och Ny TeknikLannebo Kapitalförvaltning AB | 187,872 | $3 M | — | 4.3% | +90% | Jun 30, 2026 |
| 🇸🇪 Handelsbanken Sverige Index CriteriaHandelsbanken Fonder AB | 141,242 | $2 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Harding Loevner International Small Companies PortfolioHarding Loevner LP | 100,233 | $2 M | — | 0.89% | −10% | Jul 31, 2026 |
| 🇸🇪 SEB Sverige IndexnäraSEB Funds AB | 107,514 | $2 M | — | 0.02% | +2.1% | Jun 30, 2026 |
| 🇸🇪 PLUS Mikrobolag Sverige IndexISEC Services AB | 59,809 | $1 M | — | 2.0% | new | Jun 30, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 52,803 | $1 M | — | <0.01% | −3.9% | Jul 31, 2026 |
| 🇸🇪 SEB Sverige IndexfondSEB Funds AB | 52,445 | $1 M | — | 0.03% | no change | Jun 30, 2026 |
| 🇸🇪 Länsförsäkringar Mix VisionLänsförsäkringar Fondförvaltning AB | 51,017 | $1 M | — | 0.05% | +4.3% | Jun 30, 2026 |
| 🇸🇪 Storebrand Sverige PlusStorebrand Asset Management AS | 44,590 | $1 M | — | 0.03% | no change | Jun 30, 2026 |
| 🇸🇪 Skandia Sverige ExponeringSkandia Fonder AB | 43,359 | $1 M | — | 0.03% | no change | Jun 30, 2026 |
| 🇸🇪 Storebrand Sverige Småbolag PlusStorebrand Asset Management AS | 24,123 | $0 M | — | 0.10% | +6.6% | Jun 30, 2026 |
| 🇸🇪 Storebrand SverigeStorebrand Asset Management AS | 22,645 | $0 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP | 19,959 | $0 M | — | <0.01% | +86% | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 18,723 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 20,251 | $0 M | — | 0.03% | +1.0% | Jun 30, 2026 |
| 🇸🇪 Skandia BalanseradSkandia Fonder AB | 12,517 | $0 M | — | 0.01% | no change | Jun 30, 2026 |
| 🇸🇪 Lannebo Marknad Sverige BredLannebo Kapitalförvaltning AB | 11,500 | $0 M | — | 0.03% | no change | Jun 30, 2026 |
| 🇸🇪 Skandia Världen SverigeSkandia Fonder AB | 9,373 | $0 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc. | 7,353 | $0 M | — | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP | 5,125 | $0 M | — | <0.01% | −46% | Jul 31, 2026 |
| 🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP | 3,880 | $0 M | — | <0.01% | −4.0% | Jul 31, 2026 |
| 🇸🇪 Kvartil Nordiska Småbolag+ FaktorQuartile Fonder AB | 3,090 | $0 M | — | 0.13% | +94% | Jun 30, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 2,468 | $0 M | — | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 2,319 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇸🇪 Småbolag Sverige ExponeringSkandia Fonder AB | 2,087 | $0 M | — | 0.08% | +11% | Jun 30, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 1,841 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP | 1,475 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇸🇪 Skandia FörsiktigSkandia Fonder AB | 1,206 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇸🇪 Skandia Mix 100 ExponeringSkandia Fonder AB | 1,087 | $0 M | — | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC | 999 | $0 M | — | 0.01% | no change | Jun 30, 2026 |
| 🇸🇪 Skandia Mix 60 ExponeringSkandia Fonder AB | 891 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation | 841 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street SPDR Portfolio Europe ETFSSGA Funds Management, Inc. | 536 | $0 M | — | <0.01% | −2.2% | Jun 30, 2026 |
| 🇸🇪 Avanza SwedenAvanza Fonder AB | 314 | $0 M | — | 0.01% | — | Jun 30, 2026 |
| 🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC | 246 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 41 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
CellaVision AB (publ) scorecard#
Passes 5 of the 5 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth2 of 2
- ✓Revenue grew in the newest year12.9%Revenue up 12.9% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year0.65 vs 0.56Diluted EPS 0.65 in fiscal 2025 against 0.56 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability3 of 3
- ✓Profitable in the newest year$16 MNet income $16 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median26.6%26.6% against Medical Devices's median of -8.2% (86 companies).
- ✓Return on equity above 15%18.3%18.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (esef), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from CellaVision AB (publ)'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 26.6% | -8.2% | |
| Net margin | 20.2% | -10.4% | |
| Return on equity | 18.3% | -16.8% | |
| Revenue growth | 12.9% | 10.4% | |
| Free cash flow margin | 23.9% | -1.9% |
4of 6on the Piotroski tests of financial strength
CellaVision AB (publ): financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in SEK millions; per-share figures in SEK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 759+4.9%100% | 723+6.8%100% | 677+5.9%100% | 639+13.0%100% | 566+20.0%100% | 471—100% | |
| Cost of revenue | 239+1.2%31.5% | 236+10.2%32.7% | 214+6.6%31.6% | 201+16.0%31.4% | 173+9.4%30.6% | 158—33.6% | |
| Gross profit | 520+6.7%68.5% | 487+5.2%67.3% | 463+5.6%68.4% | 438+11.7%68.6% | 392+25.3%69.4% | 313—66.4% | |
| Research and development | 98+11.6%12.9% | 87+4.9%12.1% | 83−5.9%12.3% | 89+37.8%13.9% | 64+25.4%11.4% | 51—10.9% | |
| General and administrative | 90+5.8%11.9% | 85+12.3%11.8% | 76+3.4%11.2% | 74+16.6%11.5% | 63+23.8%11.2% | 51—10.8% | |
| Operating income | 202+13.7%26.6% | 178+6.4%24.6% | 167+5.6%24.7% | 158−2.7%24.8% | 163+47.6%28.8% | 110—23.4% | |
| Income before tax | 194+9.8%25.6% | 177+7.7%24.5% | 164+10.6%24.2% | 148−6.2%23.2% | 158+41.0%28.0% | 112—23.8% | |
| Income tax | 41+14.0%5.4% | 36+6.6%5.0% | 34+12.7%5.0% | 30−8.7%4.7% | 33+44.9%5.8% | 23—4.8% | |
| Net income including minority interests | 153+8.8%20.2% | 141+8.0%19.5% | 130+10.1%19.2% | 118−5.6%18.5% | 125+40.1%22.2% | 89—19.0% | |
| Earnings per share, basic | 6.42+8.8%— | 5.90+8.1%— | 5.46+10.1%— | 4.96—— | — | — | |
| Earnings per share, diluted | 6.42+8.8%— | 5.90+8.1%— | 5.46+10.1%— | 4.96—— | — | — | |
| Shares, weighted average (basic) | 240.0%— | 240.0%— | 240.0%— | 240.0%— | 240.0%— | 24—— | |
| Dividends per share | 2.50+11.1%— | 2.250.0%— | 2.25—— | — | — | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 188+26.0%17.2% | 149+22.8%14.8% | 122+12.6%13.1% | 108−17.1%12.1% | 130+27.4%15.8% | 102—15.3% | |
| Receivables | 141+9.7%12.9% | 129+9.0%12.7% | 118−6.8%12.7% | 127+6.0%14.2% | 119+6.4%14.5% | 112—16.8% | |
| Inventory | 112−10.4%10.2% | 125−1.0%12.3% | 126−11.6%13.6% | 143+23.9%16.0% | 115+37.6%13.9% | 84—12.5% | |
| Current assets | 441+9.5%40.3% | 403+10.2%39.8% | 366−3.1%39.4% | 377+3.4%42.3% | 365+22.4%44.2% | 298—44.6% | |
| Goodwill | 121−5.8%11.0% | 128+3.5%12.6% | 124−0.3%13.3% | 124+8.8%13.9% | 114+1.9%13.8% | 112—16.8% | |
| Non-current assets | 654+7.1%59.7% | 610+8.4%60.2% | 563+9.4%60.6% | 515+11.8%57.7% | 460+24.5%55.8% | 370—55.4% | |
| Total assets | 1,095+8.1%100% | 1,013+9.1%100% | 929+4.1%100% | 892+8.1%100% | 825+23.5%100% | 668—100% | |
| Current liabilities | 111+1.7%10.1% | 109−8.4%10.8% | 119−10.5%12.8% | 133−1.0%14.9% | 135+29.1%16.3% | 104—15.6% | |
| Long-term debt | 12−5.6%1.1% | 13−55.8%1.3% | 29−52.5%3.1% | 60−37.0%6.8% | 96+10.3%11.6% | 87—13.0% | |
| Non-current liabilities | 96+9.3%8.8% | 88−5.3%8.7% | 93−20.4%10.0% | 117−20.6%13.1% | 147+9.8%17.9% | 134—20.1% | |
| Retained earnings | 865+12.1%79.0% | 772+12.7%76.2% | 685+12.6%73.7% | 608+13.1%68.2% | 537+25.0%65.1% | 430—64.3% | |
| Shareholders' equity | 888+8.8%81.1% | 816+13.9%80.5% | 716+11.7%77.1% | 642+18.1%72.0% | 543+26.5%65.8% | 430—64.3% | |
| Total equity | 888+8.8%81.1% | 816+13.9%80.5% | 716+11.7%77.1% | 642+18.1%72.0% | 543+26.5%65.8% | 430—64.3% | |
| Total liabilities and equity | 1,095+8.1%100% | 1,013+9.1%100% | 929+4.1%100% | 892+8.1%100% | 825+23.5%100% | 668—100% | |
| Shares outstanding | 240.0%— | 240.0%— | 240.0%— | 240.0%— | 240.0%— | 24—— | |
| Cash-flow statement | |||||||
| Cash from operating activities | 201+1.1%26.4% | 198+1.0%27.4% | 196+43.1%29.0% | 137−14.0%21.5% | 160+125%28.2% | 71—15.1% | |
| Capital expenditure | −19—−2.5% | −12—−1.7% | −32—−4.7% | −23—−3.7% | −14—−2.4% | −8.1—−1.7% | |
| Intangible assets bought | — | — | 0—0.0% | −0.2—−0.0% | −32—−5.6% | −0.1—−0.0% | |
| Acquisitions, net of cash acquired | — | — | — | — | 0—0.0% | −1.3—−0.3% | |
| Cash from investing activities | −86—−11.4% | −76—−10.5% | −86—−12.6% | −70—−11.0% | −84—−14.9% | −35—−7.4% | |
| Debt issued | — | — | — | — | 21+581%3.7% | 3.0—0.6% | |
| Debt repaid | −1.6—−0.2% | −29—−4.0% | −31—−4.6% | −32—−5.0% | −40—−7.1% | −29—−6.1% | |
| Dividends paid | −60—−7.9% | −54—−7.4% | −54—−7.9% | −48—−7.5% | −18—−3.2% | 0—0.0% | |
| Cash from financing activities | −75—−9.8% | −95—−13.1% | −97—−14.3% | −90—−14.1% | −48—−8.6% | −35—−7.5% | |
| Exchange-rate effect on cash | −1.0−323%−0.1% | 0.4—0.1% | −0.3−130%−0.0% | 0.9−19.3%0.1% | 1.1—0.2% | −1.0—−0.2% | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How CellaVision AB (publ) compares in Medical Devices
- Revenue$77 M · higher than 35% of 155
- Net margin20.2% · higher than 90% of 144
- Revenue growth12.9% · higher than 54% of 104
- 🇺🇸 Sight Sciences, Inc.$448 M
- 🇸🇪 Xvivo Perfusion AB (publ)$932 M
- 🇺🇸 IRadimed Corporation$1.1 B
- 🇺🇸 Sientra, Inc.$71 M
- 🇺🇸 Delcath Systems, Inc.$500 M
- 🇺🇸 ViewRay$70 M
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CellaVision AB (publ)🇸🇪 | $490 M | — | 20.2% | +12.9% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Abbott Laboratories$181.1 B
- Medtronic plc$121.2 B
- Stryker Corporation$116.5 B
- Boston Scientific Corporation$66.2 B
- Edwards Lifesciences Corporation$52.8 B
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.$27.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 15, 2026
Figures from Official annual report (ESEF), Wikidata, value.today research, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CellaVision AB (publ)? Verify and update this profile — free
Show CellaVision AB (publ)'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.